![Show Menu](styles/mobile-menu.png)
![Page Background](./../common/page-substrates/page1139.jpg)
172 patients
171 patients
343 patients
randomise
crizotinib
cisplat/carbo
pemetrexed
PROFILE trial 1014
ALK+ advanced NSCLC
BM present
BM absent
BM present
BM absent
39
132
40
131
Brain metastases in patients with ALK-positive NSCLC
BM - brain metastases
brain metastases
previously treated
Solomon
et al 2016, J Clin Oncol; 34 (24), 2858-65